Clinical trials: Mild Cognitive Impairment
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Cognitive Dysfunction, Memory Disorders
A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues.
- Trial name
- NCT07254234
- Testing
- Retinal scan, Blood test
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment
The goal of this randomized controlled trial is to determine whether the digital health app Five Lives MED can improve cognitive function in people with mild cognitive impairment (MCI).
- Trial name
- NCT06598163
- Testing
- Five Lives MED
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 170 people
- Sponsor
- SharpTx
Mild Cognitive Impairment, Alzheimer's Disease
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
REINVENT is a non-interventional, multi-center, research network-based cross-over study evaluating the potential utility of a telehealth platform in improving the efficiency of clinical trials.
- Trial name
- REINVENT (NCT02778438)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Quintiles, Inc.
Mild Cognitive Impairment, Dementia
Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild Impairment or Dementia in Primary Care
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear.
- Trial name
- NCT05380297
- Testing
- Speech analysis
- Where
- Spain
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Accexible
Mild Cognitive Impairment
Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment
This study is designed to evaluate the preliminary effectiveness and safety of a digitally based multidomain intervention in patients with MCI.
- Trial name
- NCT05059353
- Testing
- Digitally based multidomain intervention
- Where
- Singapore
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Neuroglee Therapeutics
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
MCI, Mild Cognitive Impairment
The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI)
The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for…
- Conditions
- MCI, Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- iPACES (NCT05009524)
- Testing
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- iPACES LLC
Mild Cognitive Impairment
BestBrain Evaluation of Cognitive Memory & Executive-Function
This study is intended 1. To quantify the effects of the iRemember personalized EEG-NFB therapy on working memory and executive functions in subjects with MCI by calculating the percentage of change in the Neurotrax tests…
- Trial name
- BECOME (NCT03954340)
- Testing
- iRemember Neurofeedback (NFB)
- Where
- Israel
- Volunteers
- 140 people
- Sponsor
- BestBrain Ltd.
Alzheimer Disease, Mild Cognitive Impairment
Software Validation Study-Cognitive Status Indicator
The SPARK Cognitive Status Indicator software uses an algorithm to assess a resting state EEG recording as being consistent with a cognitive status of unimpaired, mild cognitive impairment (MCI; MCI AD- or MCI AD+), or dementia…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- REMIND-V (NCT06809725)
- Testing
- SPARK Cognitive Status Indicator (software support data collected via EEG)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease
The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as…
- Trial name
- NCT07612150
- Testing
- TML-6
- Volunteers
- 210 people
- Sponsor
- Merry Life Biomedical Co., Ltd.
Brain Concussion, Mild Cognitive Impairment
Development of a Neurocognitive Screening Test
This research study will evaluate a standalone software application and is designed to standardize and validate new neurocognitive screening testing for children aged 6 through 11, and adolescents and adults ages 12 through 75.
- Trial name
- NCT02597504
- Testing
- Pen and paper neuropsychological test, Quick Test
- Where
- 4 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- ImPACT Applications, Inc.
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Mild Cognitive Impairment
Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment
This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment…
- Trial name
- INHANCE-MCI (NCT07243600)
- Testing
- Computerized speed-based cognitive training, Computerized executive function cognitive training
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Posit Science Corporation
Mild Cognitive Impairment
Efficacy of MEMORMAX in Subjects With MCI
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment.
- Trial name
- ABO-MEMO (NCT03581929)
- Testing
- Memormax
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Aboca Spa Societa' Agricola